Drug intelligence / Profile preview

adsorbed diphtheria + tetanus + acellular pertussis (3-component) combined vaccine

Development stage: Unknown
Lead developer: Wuhan Institute of Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The adsorbed diphtheria, tetanus, and acellular pertussis (3-component) combined vaccine is a biological combination product developed by Beijing Tiantan Biological Products Co., Ltd. It is intended for the active immunization of infants and children aged 2 months to 6 years against diphtheria, tetanus, and pertussis (whooping cough). The formulation utilizes an acellular pertussis component consisting of three purified antigens (typically pertussis toxin, filamentous hemagglutinin, and pertactin) rather than whole-cell bacteria, reducing reactogenicity. These antigens, along with diphtheria and tetanus toxoids, are adsorbed onto an aluminum-based adjuvant to enhance the immune response. A Phase 1 clinical trial (CTR20190714) has been conducted in China to evaluate its safety and immunogenicity compared to existing DTaP and pentavalent vaccines.

Other names: DTaP (3-component)adsorbed acellular pertussis (3-component), diphtheria and tetanus combined vaccine

Targets

FHA (Filamentous hemagglutinin)PRN (Pertactin)Diphtheria toxin

Beyond the preview

Go deeper on adsorbed diphtheria + tetanus + acellular pertussis (3-component) combined vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adsorbed diphtheria + tetanus + acellular pertussis (3-component) combined vaccine.

Explore the full profile